Literature DB >> 10694796

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.

P M Wakefield1, J M Tinsley, M J Wood, R Gilbert, G Karpati, K E Davies.   

Abstract

Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disorder caused by the lack of a subsarcolemmal protein, dystrophin. We have previously shown that the dystrophin-related protein, utrophin is able to compensate for the lack of dystrophin in the mdx mouse, the mouse model for DMD. Here, we explore whether utrophin delivered to the limb muscle of dystrophin/utrophin-deficient double knockout (dko) neonatal mice can protect the muscle from subsequent dystrophic damage. Utrophin delivery may avoid the potential problems of an immune response associated with the delivery of dystrophin to a previously dystrophin-deficient host. Dko muscle (tibialis anterior) was injected with a first generation recombinant adenovirus containing a utrophin minigene. Up to 95% of the fibres continued expressing the minigene 30 days after injection. Expression of utrophin caused a marked reduction from 80% centrally nucleated fibres (CNFs) in the uninjected dko TA to 12% in the injected dko TA. Within the region of the TA expressing the utrophin minigene, a significant decrease in the prevelance of necrosis was noted. These results demonstrate that the utrophin minigene delivered using an adenoviral vector is able to afford protection to the dystrophin/utrophin-deficient muscle of the dko mouse. Gene Therapy (2000) 7, 201-204.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10694796     DOI: 10.1038/sj.gt.3301066

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  33 in total

Review 1.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

Review 2.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

3.  ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice.

Authors:  Pauliina Kronqvist; Nobuko Kawaguchi; Reidar Albrechtsen; Xiufeng Xu; Henrik Daa Schrøder; Behzad Moghadaszadeh; Finn Cilius Nielsen; Camilla Fröhlich; Eva Engvall; Ulla M Wewer
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Fetal microchimeric cells in a fetus-treats-its-mother paradigm do not contribute to dystrophin production in serially parous mdx females.

Authors:  Elke Jane Seppanen; Samantha Susan Hodgson; Kiarash Khosrotehrani; George Bou-Gharios; Nicholas M Fisk
Journal:  Stem Cells Dev       Date:  2012-08-06       Impact factor: 3.272

5.  2015 William Allan Award.

Authors:  Kay E Davies
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

Review 6.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

Review 7.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

8.  Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.

Authors:  Guy L Odom; Paul Gregorevic; James M Allen; Eric Finn; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

9.  Gene transfer establishes primacy of striated vs. smooth muscle sarcoglycan complex in limb-girdle muscular dystrophy.

Authors:  Madeleine Durbeej; Shanna M Sawatzki; Rita Barresi; Kathleen M Schmainda; Valérie Allamand; Daniel E Michele; Kevin P Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-08       Impact factor: 11.205

10.  Oral quercetin administration transiently protects respiratory function in dystrophin-deficient mice.

Authors:  Joshua T Selsby; Christopher G Ballmann; Hannah R Spaulding; Jason W Ross; John C Quindry
Journal:  J Physiol       Date:  2016-05-29       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.